Cardioprotective effect of iron chelators

Advances in Experimental Medicine and Biology

Volumn 509, Issue , 2003, Pages 77-89

  Hershko, Chaim ^a   Link, Gabriela ^b   Konijn, Abraham M ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 5' NUCLEOTIDASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA TOCOPHEROL; AMINO ACID; ASCORBIC ACID; CARBONYL DERIVATIVE; CARDIOLIPIN; CELL ENZYME; CELL PROTEIN; CYTOCHROME B5 REDUCTASE; CYTOPLASM PROTEIN; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; FERRIC ION; FERRITIN; FREE RADICAL; HEMOGLOBIN; HYDROGEN PEROXIDE; IRON; IRON CHELATE; MALONALDEHYDE; MESSENGER RNA; PENTETIC ACID; POLYUNSATURATED FATTY ACID; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRANSFERRIN RECEPTOR; UBIQUINOL CYTOCHROME C REDUCTASE; UNINDEXED DRUG; CARDIOTONIC AGENT; IRON CHELATING AGENT;

CELL LEVEL; CONTINUOUS INFUSION; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROPOIESIS; EYE TOXICITY; HEART INJURY; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIFE EXPECTANCY; LIPID PEROXIDATION; NONHUMAN; OUTCOMES RESEARCH; OXIDATIVE STRESS; PARENCHYMA; PATHOPHYSIOLOGY; PHLEBOTOMY; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; RETINA DISEASE; REVIEW; SURVIVAL RATE; THALASSEMIA; ANIMAL; HEART; HEART DISEASE; HEART MUSCLE; IN VITRO STUDY; METABOLISM;

ANIMALS; CARDIOTONIC AGENTS; HEART; HEART DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYOCARDIUM; THALASSEMIA;

EID: 0042309616     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (83)

1. Gabutti V, Piga A: Results of long-term iron chelating therapy. Acta Haemat 1996; 95: 26-36.
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331: 574-578.
3. Pietrangelo A. Mechanism of iron toxicity. In Chaim Hershko Ed. Iron Chelating Therapy. Kluwer Academic/Plenum Publishers. New York.
4. Brissot P. Role of NTBI in the pathogenesis of iron toxicity and hemosiderosis. In Chaim Hershko Ed. Iron Chelating Therapy. Kluwer Academic/Plenum Publishers. New York.
5. Cabantchik ZI. Identification and quantitation of the chelatable iron pool. In Chaim Hershko Ed. Iron Chelating Therapy. Kluwer Academic/Plenum Publishers. New York.
6. Porter J. Results of long-term iron chelating therapy with deferoxamine. In Chaim Hershko Ed. Iron Chelating Therapy. Kluwer Academic/Plenum Publishers. New York.
7. Cook JD, G. Marsaglia JW, Eschbach et al. Ferrokinetics: A biologic model for plasma iron exchange in man. J. Clin. Invest. 1970; 49: 197-205.
8. Hershko C, Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Brit J Haematol 1979; 42: 125-132.
9. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Brit J Haematol 1978; 40: 255-263.
10. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin bound iron (NTBPI) Anal Biochem 1990; 186: 320-323.
11. Anuwatanakulchai M, Pootrakul P, Thuvasethakul P, Wasi P. Non-transferrin plasma iron in ? -thalassaemia/HbE and haemoglobin H diseases. Scand J Haematol 1984, 32: 153-158.
12. Wagstaff M., Peters SW, Jones BM, Jacobs A. Free iron and iron toxicity in iron overload. Brit J Haematol 1985; 61: 566-567.
13. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular- weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985; 68: 463-467.
14. Al-Refaie, FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Brit J Haemat 1992; 82: 431-436.
15. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88: 705-713.
16. Link, G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985; 106: 147-153.
17. Randell, EW, Parkes JG, Olivieri NF, Templeton DM. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 1994; 269: 16046-16053.
18. Link G, Athias P, Grynberg A, Pinson A, Hershko C. Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture. J Lab Clin Med 1989; 113: 103-111.
19. Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Molec Pharm 1992; 42: 703-710.
20. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72: 19-28.
21. Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Letters 1997; 382: 304-308.
22. Hershko C, Weatherall JD. Iron chelating therapy. CRC Critical Reviews in Cinical Laboratory Sciences. CRC Press Inc. Boca Raton, Florida. Vol 26, Issue 4, 1988: 303-345.
23. Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C. IRC11, a new synthetic chelator with selective interaction with catabolic red blood cell iron. Evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. Blood 1997; 90: 4180-4187.
24. Leibold EA, Guo B. Iron-dependent regulation of ferritin and transferrin receptor expression by the iron-responsive element binding protein. Ann Rev Nutr 1992; 12: 345-368.
25. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: The control of cellular iron metabolism. Cell 1993; 72: 19-28.
26. Cairo G, Rappocciolo E, Tacchini L, Schiaffonati L. Expression of the genes for the ferritin H and L subunits in rat liver and heart. Evidence for tissue-specific regulations at pre-and post-translational levels. Biochem J 1991; 275: 813-816
27. Moreb J, Hershko C, Hasin Y. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells. Basic Res in Cardiol 1988; 83: 360-368.
28. Hershko C, Link G, Pinson A. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid, and ? -tocopherol in iron-loaded rat myocardial cell cultures. J Lab Clin Med 1987;110: 355-361.
29. Link G, Pinson A, Kahane I, Hershko C. Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: Effect of ascorbate and ? -tocopherol on myocardial lipid peroxidation. J Lab Clin Med 1989; 114: 243-249.
30. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture. Blood 1991; 77: 2049-2055.
31. Link G, Athias P, Grynberg A, Hershko C Pinson A. Iron loading modifies ? -adrenergic responsiveness of cultured ventricular myocytes. Cardioscience 1991; 2: 27-30.
32. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview, in L Packer, AN Glazer eds. Methods in Enzymology 1990; 186: 1-85.
33. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 1990; 9: 315-325.
34. Goddard JG, Sweeney GD. Ferric nitriloacetate: a potent stimulant of in vivo lipid peroxidation in mice. Biochem Pharm 1983; 32: 3879-3882.
35. Dillard CJ, Downey JE, Tappel AL. Effect of antioxidants on lipid peroxidation in iron-loaded rats. Lipids 1984; 19: 127-33.
36. Mak IT, Weglicki WB. Characterization of iron-mediated peroxidative injury in isolated hepatic lysosomes. J Clin Invest 1985; 75: 58-63.
37. Seymour CA, Peters TJ. Organelle pathology in primary and secondary hemochromatosis with special reference to lysosomal changes. Brit J Haemat 1978; 40: 239-253.
38. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 1993; 121: 127-134.
39. Link G, Pinson A, Hershko C: The ability of orally effective iron chelators dimethyl-and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood 1994; 83: 2692-2697.
40. Houglum K, Filip M, Witztum JL, Choikier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990; 86: 1991-1998.
41. Schauenstein E, Esterbauer H, Zoliner H. Aldehydes in Biological Systems. Pion Limited, London. 1977, p 102
42. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M: Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1995; 1271: 67-74.
43. Ceccarelli D, Gallesi D, Giovannini F, Ferrali M, Masini A. Relationship between free iron level and rat liver mitochondrial dysfunction in experimental dietary iron overload. Biochem Biophys Res Comm 1995; 209: 53-59.
44. Bacon BR, O'Neill R, Britton RS. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993; 105: 1134-40.
45. Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 1998; 131: 466-474.
46. Robinson BH, Glerum DM, Chow W, Petrova-Benedict R, Lightowlers R, Capaldi R. The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lactic acidemia. Ped Res 1990; 28: 549-555.
47. Hatefi Y. Preparation and properties of NADH:ubiquinone oxidoreductase (complex I) ECI6.5.3. in S Fleisher, L Packer eds. Methods in Enzymology 1978; 53: 11-14.
48. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 1990; 265: 16330-16336.
49. Kadiiska MB, Burkitt MJ, Qun-Hui Xiang, Mason RP. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest 1995; 96: 1653-1657.
50. Fry M, Green DE. Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Biochem Biophys Res Comm 1980; 93: 1238-1246.
51. Goormaghtigh E, Brasseur R, Ruysschaert JM. Adriamycin inactivates cytochrome C oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Comm 1982; 104: 314-320.
52. Heales SJR, Davies SEC, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 1995; 20: 31-38.
53. Zager A. Mitochondrial free radical production induces lipid peroxidation during myohemoglobinuria. Kidney Internal 1996; 49: 741-751.
54. Pitkainen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 1996; 98: 345-351.
55. Reynolds LG. Diagnosis and management of acute iron poisoning. Clin Haematol 1989; 2: 423-434.
56. Heys AD, Dormandy TL. Lipid peroxidation in iron loaded spleens. Clin Sci 1981; 60: 295-301.
57. O'Connell MJ, R.J. Ward RJ, Baum H, Peters TJ. The role of iron in ferritin-and haemosiderin-mediated lipid peroxidation in liposome, Biochem J 1985; 229: 135-139.
58. Nienhuis AW. Vitamin C and iron. N Engl J Med 1981; 304: 170-171.
59. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Clin Haemat 1994; 7: 919-940.
60. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850: 227-231.
61. Hoffbrand AV, Wonke B. Results of long-term subcutaneous desferrioxamine therapy. Bailliere's Clin Haemat 1989; 2: 345-359.
62. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New Engl J Med 1994; 331: 567-569.
63. Giardina PJ, Grady RW, Ehlers KH, Burstein S, Graziano JH, Markenson AL, Hilgartner MW. Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine, In: A. Bank, Ed. Sixth Cooley's Anemia Symposium, Ann N YAcad Sci 1990; 612: 275-285.
64. Calleja EM, Shen JY, Lesser M, Grady RW, New MI, Giardina PJ. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Ann N Y Acad Sci 1998; 850: 469-470.
65. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984; 1: 392.
66. Hyman CB, Agness CL, Rodriguez-Funes R, Zednikova M. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia, Ann NY Acad Sci 1985; 445: 293-303.
67. Cohen AR, Martin M, Schwartz E. Current treatment of Cooley's anemia. Intravenous chelation therapy. In: A. Bank, Ed. Sixth Cooley's Anemia Symposium, Ann N Y Acad Sci 1990; 612: 286-292.
68. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000;95:1229-36
69. Araujo A, Kosaryan M, MacDowell A, Wickens D, Puri S, Wonke B, Hoffbrand AV. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overkload. Brit J Haematol 1996; 93: 835-837.
70. Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 1993; 103: 1276-1278
71. Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen IJ, Zaizov R Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients. Isr J Med Sci 1994; 30: 658-664
72. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. Am J Hematol 1992; 41: 61-63
73. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113-117.
74. Cohen AR, Mizanin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989; 115: 151-155.
75. de Montalembert M, Jan D, Clairicia M, Hannedouche T, Sidi D, Girot R. Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-a-Cath). Arch Fr Pediatr 1992; 49: 159-163.
76. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine ototoxicity: evaluation of risk factors in thalasaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403-409.
77. Marti V, Ballester M, Marrugat J, Auge JM, Padro JM, Narula J, Caralps JM Assessment of the appropriateness of the decision of heart transplantation in idiopathic-dilated cardiomyopathy. Am J Cardiol 1997;80:746-750
78. Koerner MM, Tenderich G, Minami K, zu Knyphausen E, Mannebach H, Kleesiek K, Meyer H, Koerfer R. Heart transplantation for end-stage heart failure caused by iron overload. Br J Haematol 1997; 97: 293-296
79. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disese by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312, 1600-1603.
80. Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, Harper RW. Prevention of heart disese by subcutaneous desferrioxamine in patients with thalassemia major. Aust N Z J Med 1993; 23: 656-661.
81. Modell B, Khan M, Darlison M. Survival in ? -thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 2000; 355: 2051-2052.
82. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakathul N, Jackson BFA, Cochrane J et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
83. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Brit J Haematol 1998; 103: 361-364.